改良 Kessler 缝合法治疗Ⅱ区指屈肌腱断裂

目的：观察改良 Kessler 缝合法治疗Ⅱ区指屈肌腱断裂的临床疗效和安全性。方法：Ⅱ区指屈肌腱断裂患者78例,随机分为2组,每组39例,分别采用改良 Kessler 缝合法和常规缝合法缝合断裂肌腱。术后观察2组患者肌腱愈合、患指功能恢复及并发症发生情况,并对2组的疗效和并发症发生率进行比较。结果：78例均获随访,随访时间3-6个月,依据中华医学会手外科学分会手部肌腱修复后评定标准评价疗效,改良 Kessler 缝合组,优25例、良11例、可2例、差1例;常规缝合组,优15例、良12例、可8例、差4例。改良 Kessler 缝合组疗效优于常规缝合组（Z =﹣2.654,p =0.008）。改良 Kessler 缝合组创面均一期愈合。常规缝合组,术后并发浅表感染2例,经换药愈合;并发深度感染1例,经拆除缝线、行负压封闭引流后愈合;并发肌腱再断裂2例,改行改良 Kessler 缝合后愈合。2组间并发症发生率比较,改良 Kessler 缝合组小于常规缝合组（ p =0.027）。结论：改良Kessler 缝合法治疗Ⅱ区指屈肌腱断裂,有利于肌腱愈合和患指功能恢复,并发症少,疗效优于常规缝合法。     

《黄帝内经》脉学理论探析

《黄帝内经》是古籍医学集大成者,其中阐述了大量的脉学理论,这些理论是中医学理论的重要组成部分,因此准确的把握其中的脉学理论对提高自己的脉学水平有重要的作用。本文通过对《黄帝内经》脉学相关文献的研究,重点总结了其中的脉学理论,以期能为脉学学习提供帮助。     

滕晶教授治疗失眠经验拾零

失眠是现实生活中比较常见的一类疾病,随着社会节奏的加快,生活压力逐渐增大,几乎每个成年人都有失眠的经历,笔者从师滕晶教授,耳濡目染通过自身的学习,习得滕晶教授治疗失眠经验一二,共飨读者。     

Panax notoginseng saponins (PNS) inhibits breast cancer metastasis

Ethnopharmacological relevance

Panax notoginseng (Burkill) F.H. Chen (Araliaceae) has been extensively used as a therapeutic agent to treat a variety of diseases. Panax notoginseng saponins (PNS) consist of major therapeutically active components of Panax notoginseng. PNS inhibit the growth of a variety of tumor cells in vitro and in vivo. The aim of the study is to investigate the effects and underlying mechanisms of PNS on breast cancer metastasis.

Materials and methods

4T1 cell, a highly metastatic mouse breast carcinoma cell line, was utilized for in vitro and in vivo assays. In vitro assays were first performed to examine the effects of PNS on 4T1 cell viability, migration and invasion, respectively. Real-time PCR analyses were also performed to examine the effects of PNS on the expression of genes associated with tumor metastasis. The effect of PNS on 4T1 tumor cell metastasis was further assessed in spontaneous and experimental metastasis models in vivo.

Results

PNS treatment exhibited a dose-dependent effect on impairing 4T1 cell viability in vitro. However, when examined at a lower dose that did not affect cell viability, the migration and invasion of 4T1 cell was remarkably inhibited in vitro. Meanwhile, PNS treatment led to upregulated expression of genes known to inhibit metastasis and downregulated expression of genes promoting metastasis in cultured 4T1 cells. These results suggested a selective effect of PNS on 4T1 migration and invasion. This hypothesis was further addressed in 4T1 metastasis models in vivo. The results showed that the lung metastasis was significantly inhibited by PNS treatment in both spontaneous and experimental metastasis models.

Conclusion

Taken together, our results demonstrated an inhibitory effect of PNS on 4T1 tumor metastasis, warranting further evaluation of PNS as a therapeutic agent for treating breast cancer metastasis.     

Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population

Glioma is the most common type of primary brain malignancy in adults. The anti-apoptotic protein B-cell lymphoma 2 (BCL2) has been implicated in the pathogenesis of glioma. This study aimed to evaluate the potential association between BCL2-938C>A genetic polymorphism and glioma susceptibility. This case–control study was conducted in Chinese Han populations consisting of 248 glioma cases and 252 cancer-free controls. The BCL2-938C>A genetic polymorphism was detected by the polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) and verified using DNA sequencing methods. Our data suggested that the genotype/allele of BCL2-938C>A polymorphism were statistically associated with the increased risk of glioma where the risk of glioma for genotype AA or allele A is significantly higher than wild genotype CC (odds ratio (OR)?=?2.23, 95 % confidence interval (CI) 1.21–4.10, p?=?0.009) or allele C (OR?=?1.39, 95 % CI 1.06–1.82, p?=?0.016), respectively. In addition, the BCL2-938AA genotype was significantly more common in patients with glioblastoma and in patients with grade IV glioma. Our findings indicate that the BCL2-938C>A polymorphism is associated with the susceptibility to glioma in Chinese Han populations and might be used as molecular markers for evaluating glioma risk.     

MV3和HaCaT细胞接种去表皮真皮组织上构建人工皮肤黑素瘤模型

文章亮点：1以往研究人工皮肤肿瘤组织模型所用的皮肤种子细胞多是分离于人皮肤的角质形成细胞,但是由于供体及伦理的原因使这种直接从皮肤上分离角质细胞建立皮肤模型的方法有一定局限性,而且,因种子细胞的供体及部位不同,其建立的皮肤模型可能存在着差异。     

Oral Immunization with Lactobacillus casei Expressing the Porcine Circovirus Type 2 Cap and LTB Induces Mucosal and Systemic Antibody Responses in Mice

Porcine circovirus type 2 (PCV2) causes many diseases in weaned piglets, leading to serious economic losses to the pig industry. This study investigated the immune response following oral administration of Lactobacillus casei ATCC393 (L. casei 393) expressing PCV2 capsid protein (Cap) fusion with the Escherichia coli heat-labile toxin B subunit (LTB) in mice. Recombinant L. casei strains were constructed using plasmids pPG611.1 and pPG612.1. The expression and localization of proteins from recombinant pPG611.1-Cap-LTB (pPG-1-Cap-LTB)/L. casei 393 and pPG612.1-Cap-LTB (pPG-2-Cap-LTB)/L. casei 393 were detected. All recombinant strains were found to be immunogenic by oral administration in mice and developed mucosal and systemic immune responses against PCV2. The titers of specific antibodies in mice administered pPG-2-Cap-LTB/L. casei 393 were higher than those in mice administered pPG-1-Cap-LTB/L. casei 393 in serum and the mucosal samples. The mucosal immune response was not only limited to the gastrointestinal tract but was also generated in other mucosal parts. Thus, the application of recombinant L. casei could aid in vaccine development for PCV2.     

人HCN4基因重组腺病毒载体的构建和鉴定

目的: 构建超极化激活环核苷酸门控通道基因(HCN4)重组腺病毒载体. 方法: 采用基因工程技术,将HCN4 cDNA定向克隆至穿梭载体pAdTrack-CMV中,利用pAdeasy-1系统进行细菌内同源重组后,脂质体转染293T细胞包装、扩增,CsC1密度梯度超速离心纯化. 采用PCR方法对重组腺病毒进行鉴定,利用穿梭质粒中带有绿色荧光蛋白GFP报告基因,对病毒滴度和感染效率进行监测. 结果: 测序结果证明成功构建了HCN4基因重组腺病毒载体,病毒滴度达2.0×1015pfu/L. 结论: 应用细菌内同源重组法成功构建了含人HCN4基因的重组腺病毒载体.     

Interleukin-12 gene modification exerts anti-tumor effects on murine mammary sarcoma cell line in vivo

The aim of this project was to investigate the anti-tumor effect of an IL-12 gene modified mammary sarcoma murine cell line, EMT6/IL-12, in mouse model. In this study, we transfected the recombinant eukaryotic plasmid encoding IL-12 gene （pcDNA6-p70） into EMT6 and obtained the IL-12 expressing EMT6/IL-12 cell line. Then EMT6/IL-12 cells were s.c. inoculated into mice. The recombinant vector treatment group was set as control. We then evaluated the inhibition of tumor growth and the anti-tumor immunity function in vivo such as cytotoxicity, proliferation of splenocytes and serial IFN-T level. And the percentage of IFN-T producing CD4 or CD8 T cells among splenocytes was also analyzed in tumor bearing mice. Our results showed that the growth of tumors was obviously inhibited in EMT6/IL-12 group. Moreover, the capacities of anti-tumor immunity were all significantly higher in EMT6/IL-12 group compared to the controls. The results of the present investigation support the notion that EMT6/IL-12 could exert gene therapy in tumor model by improving the anti-tumor cellular immunity.